Zydus Lifesciences Limited has informed the Exchange about Investor Presentation
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences reported Q1 FY26 revenue of Rs. 65,737 mn, up 6% YoY but just 0.7% QoQ. EBITDA was nearly flat at Rs. 20,885 mn with margin contracting to 31.8% from 33.6% YoY, while gross margin slipped to 72.8% from 74.4%. Net profit rose 3.3% YoY to Rs. 14,668 mn. India Formulations grew 8% YoY, US Formulations 2.9% YoY ($371 mn), Consumer Wellness was weak at 2.2% YoY on monsoon impact, and International Markets surged 36.8% YoY. R&D spend rose 24% YoY to Rs. 4,856 mn. Net cash strengthened to Rs. 56,312 mn. Key strategic updates include the completed acquisition of France-based Amplitude Surgical (MedTech) and plans to acquire Agenus Inc's US biologics manufacturing facilities for $75 mn upfront plus $50 mn contingent, marking entry into global biologics CDMO.
Stable top-line growth with margin pressure — flat EBITDA despite revenue growth signals cost headwinds from higher employee and R&D expenses. The Amplitude Surgical and Agenus deals show ambitious diversification into MedTech and biologics CDMO, which could drive future growth but adds integration risk. Strong net cash and zero-debt position support continued inorganic moves.